This article is available online at http://www.jlr.org of an epoxide hydrolase (EH) and a lipid phosphatase in each of its subunits ( 2-4 ). The sEH is abundantly expressed throughout the organism ( 5, 6 ) and accepts a broad range of substrates ( 7, 8 ) , in particular, endogenous epoxides derived from unsaturated fatty acids such as epoxyeicosatrienoic acids (EETs) ( 9 ). The organism utilizes these lipid epoxides as important signaling molecules, which regulate a variety of physiological functions. EETs were identifi ed as endothelium-derived hyperpolarizing factors (EDHFs) ( 10 ) acting on vascular smooth muscle cells leading to hyperpolarization and vasodilation ( 11, 12 ) . Since then, several experimental hypertensive models confi rmed a role for EETs in blood pressure regulation and end organ protection ( 13, 14 ) . Further, EETs have anti-infl ammatory and antinociceptive properties ( 15-17 ) and fi nally, seem to promote cell proliferation, migration, and angiogenesis (18) (19) (20) .
hepoxilin-generating 12R-LOX pathway in the skin are associated with a congenital form of ichthyosis (42) (43) (44) (45) (46) . A hepoxilin receptor has not been identifi ed, but several reports ( 34, (47) (48) (49) support its existence.
Here, we report that 12S-LOX-derived HxA 3 and HxB 3 are effi ciently converted to the corresponding trioxilins by sEHs. Our results suggest a biological relevance of sEH, rather than hepoxilin hydrolase, in hepoxilin metabolism, which opens a new branch in the numerous physiological functions of sEH.
METHODS

Enzyme assays
Human full length sEH containing an N-terminal Strep-Tag and rat sEH containing an N-terminal His-Tag were cloned, recombinantly expressed in Escherichia coli , and purifi ed as described previously ( 3 ) . Epoxide hydrolase activity was measured using 8(R,S)-Hydroxy-11S,12S-epoxyeicosa-5Z,9E,14Z-trienoic acid (HxA 3 ) and 10(R,S)-Hydroxy-11S,12S-epoxyeicosa-5Z,8Z,14Z-trienoic acid (HxB 3 ) as substrates by determining the formation of the corresponding diols 8(R,S)-Hydroxy-11,12-dihydroxyeicosa-5Z,9E,14Z-trienoic acid (TrxA 3 ) and 10(R,S)-Hydroxy-11,12-dihydroxyeicosa-5Z,8Z,14Z-trienoic acid (TrxB 3 ). Typically, 5-50 ng purifi ed sEH or 10-100 µg organ extracts were incubated with various concentrations of HxA 3 and HxB 3 ranging from 0.1 µM to 30 µM with or without inhibitor in 50 mM Tris HCl, 50 mM NaCl, 2% glycerol, pH 7.4 in a fi nal volume of 50 µl for 10 min at 37°C. The reaction was stopped by addition of 2 vols of methanol and samples were pelleted for 5 min at 13,000 rpm prior to LC-MS/MS analysis. Substrate turnover was determined using inter-3.3.2.7) was partly purifi ed from rat liver cytosol and identifi ed as the main hydrolase of the endogenous lipid hepoxilin A 3 . The authors further discriminated hepoxilin hydrolase from other EHs due to its size (53 kDa) and substrates preference for hepoxilin A 3 compared with leukotriene or styrene oxide ( 30 ) . To date, the enzyme is only incompletely characterized and no structural or sequence information is available.
Most enzymatic-derived endogenous lipid epoxides are of cis -confi guration, but also some trans -substitutes lipid epoxides are formed within the organism, such as the infl ammatory mediator leukotriene A 4 . The trans -epoxy hydroxy eicosanoids hepoxilin A 3 and B 3 (HxA 3 and HxB 3 ) are formed from arachidonic acid through the 12-lipoxygenase (LOX) pathway ( Fig. 1 ) in various organs like liver, brain, lung, pancreas, and skin ( 9, 31 ) . They can be transformed to the corresponding trihydroxy metabolites (trioxilins, Trx ) or glutathione conjugates ( 32 ) .
Early studies showed a hepoxilin-mediated increased insulin release from pancreatic islets ( 33 ) . In the brain, hepoxilins modulate synaptic neurotransmission and neuronal excitability, mostly through stimulation of intracellular calcium release or increased calcium infl ux into the cell (34) (35) (36) (37) . Hepoxilins are considered pro-infl ammatory because increased hepoxilin and trioxilin levels have been found in psoriatic lesions ( 38 ) and HxA 3 was shown to regulate neutrophil migration in response to infl ammation ( 39, 40 ) . Several reports suggest an involvement of these lipid mediators in epidermal differentiation and skin barrier function ( 41 ) . Interestingly, mutations in the Supplemental Material can be found at: 2 ml acetonitrile and 2 ml ddH 2 O. Columns were washed with 1 ml ddH 2 O and evaporated to dryness. Lipids were eluted with 3 × 600 l ethylacetate, dried under a stream of nitrogen, dissolved in acetonitrile, and pelleted for 2 min at 13,000 rpm prior to LC-MS/MS analysis as described above. In some cases, liver homogenates were treated with 30 M arachidonic acid at 37°C for 30 min and lipids were isolated by solid phase extraction as described above.
Western blot
Protein samples in Laemmli buffer were subjected to SDS-PAGE and semi-dry blotting following standard procedures. Blots were incubated with polyclonal sEH rabbit antiserum for 2 h (dilution of 1:1000) in Tris-buffered saline containing 0.5% Tween-20. An alkaline phosphatase conjugated anti-rabbit antibody (Sigma Aldrich) was applied at a dilution of 1:30000 followed by colorimetric detection using 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium chloride (NBT) .
RESULTS
sEH effi ciently turns over HxA 3 and HxB 3 Human and rat sEH were cloned, recombinantly expressed in E. coli , and purifi ed to homogeneity using affi nity chromatography as described previously ( 3 ) . To determine the effect of purifi ed recombinant rat or human sEH on hepoxilin metabolism, we used LC-MS/MS analysis followed by kinetic evaluation. Human or rat sEH was incubated with various concentrations of HxA 3 and HxB 3 with or without inhibitor and samples were analyzed by LC-MS/MS. HxA 3 was effi ciently hydrolyzed by purifi ed rat soluble epoxide hydrolase with a V max of 1.7 µmol/mg/ min, a K m of 5 µM, and a catalytic effi ciency of 4.5 × 10 5 as shown in Fig. 2 . Both HxA 3 and HxB 3 are substrates for purifi ed rat sEH and also human sEH ( Fig. 2 ) and a summary of the kinetic parameters is presented in Table 1 .
Hepoxilin hydrolase activity is linked to sEH presence
To evaluate the physiological contribution of sEH to hepoxilin metabolism, we separated mouse liver cytosolic fractions using gel permeation chromatography and tested each elution fraction for the metabolism of HxA 3 , 14,15-EET, and 5,6-EET. Each fraction was further assayed for the presence of sEH by Western blot analysis ( Fig. 3 ). The hepoxilin hydrolase and sEH activities show 100% coelution from the column. Moreover, the fraction with the highest hepoxilin hydrolase activity also contains the highest amount of sEH ( Fig. 3 , lower panel).
Hepoxilin turnover is inhibited by sEH but not mEH inhibitors
To characterize the physiological contribution of sEH to hepoxilin metabolism, we used a selection of epoxide hydrolase inhibitors. The hepoxilin turnover by purifi ed sEH was effectively inhibited by sEHIs as shown in Fig. 4 . Hepoxilin metabolism in liver protein extracts from wildtype (WT) animals was inhibited by ACU and AUDA but not the mEH inhibitor valpromide, as shown in Fig. 5 . In addition, ACU inhibited hepoxilin metabolism by purifi ed rat sEH and liver cytosolic preparations with an IC 50 value nal HxA 3 and HxB 3 standards. EH activity against EETs was performed as described previously ( 50 ) . Kinetic constants were calculated by kinetic modeling based on the equation V = E × CS/(CS+ K m ) (with V = % turnover of V max , E = total amount of enzyme, CS = substrate concentration, and K m = Michaelis Menten constant). Variations were calculated from four to fi ve independent experiments using freshly prepared enzyme preparations.
Lipid substrates were purchased from Biomol except for TrxA 3 and TrxB 3 , which were synthesized biochemically using purifi ed sEH. One microgram of HxA 3 or HxB 3 was turned over to the corresponding diol using 200 ng sEH in 50 mM Tris HCl, 50 mM NaCl, 2% glycerol, pH 7.4 in a fi nal volume of 500 µl for 30 min at 37°C. The reaction products were extracted three times with 2 vols of ethyl acetate, dried under a stream of nitrogen, and reconstituted in methanol.
LC-MS/MS analysis
Separation of analytes was performed on an Agilent eclipse XDB-C18 reverse phase column (4.6 × 150 mm, 5 m pore size) with a corresponding opti-gard precolumn using an Agilent 1100 liquid chromatography system. The mobile phase consisted of (A) 0.1% formic acid and (B) acetonitrile containing 0.1% formic acid at a fl ow rate of 400 l/min using an injection volume of 20 l. Starting conditions of 70% buffer B were maintained for 2 min followed by a linear gradient from 70 to 100% B within 7 min. An isocratic fl ow of 100% B was held for 1.5 min and fi nally the column was re-equilibrated for 2 min with 70% B. The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole linear ion trap mass spectrometer (Applied Biosystems) equipped with a TurboV source and electrospray (ESI) interface. Analytes were recorded using multiple reaction monitoring in negative mode ( Ϫ MRM) using the following source specifi c parameters: IS Ϫ 4500V, TEM 450°C, curtain gas (CUR = 30), nebulizer gas (GS1 = 50), heater gas (GS2 = 70) and collision gas (CAD = 10). The compound specifi c parameters for the different substrates (as specifi ed in supplemental material) were determined by direct infusion of standard solutions (100-300 ng/ml) in methanol at a fl ow rate of 10µl/min using the quantitative optimization function of the Analyst software 1.4.2. Samples were quantifi ed by determining the peak area under the curve (AUC ) with the quantifi cation function of the Analyst software 1.4.2 using the transitions as specifi ed in the supplementary online material. The background noise was assessed by analyzing blank samples and standard curves were generated using blank samples spiked with a series of control lipids ranging from 1 to 1,000 ng/ml. For HxA 3 , HxB 3 , TrxA 3 , and TrxB 3 , the limit of detection ranged from 4 to 20 pg and the limit of quantifi cation from 15 to 65 pg, corresponding to a signal-to-noise ratio of 3 and 10, respectively.
Organ extracts
C57BL/6 mice were obtained from the Institute of Laboratory Animal Sciences, University of Zurich and C57BL/6 sEH Ϫ / Ϫ mice ( 51 ) were kindly provided by Dr. F. J. Gonzales (National Institutes of Health, Bethesda, MD). Six-to ten-week-old male mice were euthanized by cervical dislocation and livers were excised and homogenized in ice-cold phosphate buffered saline, pH 7.4. All subsequent steps were performed at 4°C. Cytosolic and microsomal fractions were prepared by ultracentrifugation of the 9,000 × g supernatant of the liver homogenates at 100,000 × g for 45 min.
Hepoxilin/trioxilin contents of livers of WT and sEH
؊ / ؊ mice in vivo Lipids were extracted from liver organ preparations of sEH WT and sEH Ϫ / Ϫ mice with or without pretreatment with arachidonic acid followed by LC-MS/MS analysis of the lipids. Liver homogenates of sEH Ϫ / Ϫ mice show a signifi cantly elevated basal level of HxB 3 but lowered levels of trioxilins compared with the WT animals ( Fig. 7A ) , where trioxilins are readily formed. After arachidonic acid treatment of organ extract, the synthesis of hepoxilin precursors is greatly induced (40-fold) and the accumulation of hepoxilins in liver homogenates from sEH Ϫ / Ϫ mice is even more pronounced ( Fig. 7B ).
DISCUSSION
Here, we report for the fi rst time that trans -hydroxyepoxy lipids, in particular the endogenous 12S-LOX-derived lipid mediators HxA 3 and HxB 3 , are excellent substrates for mammalian sEH and converted to the corresponding trioxilins. 12R-LOX-derived hepoxilins, which are specifically generated in skin, are most likely preferred sEH substrates, although they have not been tested to date. sEH of ‫ف‬ 1 nM (data not shown), which is in line with previously reported data ( 52 ) . In microsomal preparations of sEH, WT mice hepoxilin turnover amounted to 30% compared with the cytosolic fraction. Western blot analysis of microsomal and cytosolic liver preparations confi rmed the presence of sEH protein in both liver fractions, although to signifi cantly lower amount in microsomes (data not shown). Furthermore, purifi ed mEH, which is highly abundant in the liver, does not show any activity against hepoxilins (data not shown).
sEH is responsible for hepoxilin metabolism
To investigate the quantitative contribution of sEH to hepoxilin turnover, we incubated protein extracts isolated from livers of sEH WT and sEH Ϫ / Ϫ mice with HxA 3 and HxB 3 . Hepoxilin turnover to trioxilins was greatly abolished in sEH Ϫ / Ϫ mice compared with the WT mice ( Fig. 6 ).
Specifi cally, in both cytosolic and microsomal liver preparations of sEH Ϫ / Ϫ mice, the activity toward HxA 3 and HxB 3
was greatly reduced compared with the WT mice. Again, the activity toward hepoxilins in liver microsomal preparations of WT animals is explained by the presence of some sEH whereas no sEH protein was detectable in the sEH
mice by immunoblotting (data not shown). Western blot revealed that the hepoxilin hydrolase activity is linked to sEH presence, showing a perfect match. The double peak in the activity profi le can be explained by the presence of monomeric and dimeric sEH in liver cytosol. These results suggested that mammalian sEH, rather than hepoxilin hydrolase, is the key enzyme responsible for hepoxilin metabolism in mouse liver.
To strengthen our hypothesis, we analyzed liver extracts from sEH WT and sEH Ϫ / Ϫ mice. Hepoxilin turnover was greatly abolished compared with the WT animals. The activity against hepoxilins found in the liver microsomal preparation of WT animals can be explained by the presence of sEH due to its partial peroxisomal localization in liver ( 54, 55 ), which we confi rmed by Western blot analysis.
metabolizes hepoxilins with a catalytic effi ciency that is within the range of turnover of its previously identifi ed physiological substrates, EETs, which are among the best endogenous substrates for sEH. The activity of mammalian sEH against EETs lies in the range of 1-20 µmol/mg/ min. We do not see a negative cooperativity with both hepoxilins, as has been suggested for the EET turnover by sEH ( 50 ) . Human sEH turns over hepoxilins less effi ciently (by a factor of three) than rat sEH. This has been seen for other substrates and might be explained by a compensatory effect due to the lower expression level of sEH in rat liver compared with human liver. HxA 3 is a better substrate for mammalian sEH than HxB 3 . The hydroxy group positioned directly next to the epoxide might pose a sterical hindrance leading to less effi cient turnover by sEH. The sEH turns over hepoxilins orders of magnitude more effi ciently than the previously reported hepoxilin hydrolase that displayed a specifi c activity of 0.2 nmol/mg/min. Hepoxilin hydrolase was partly purifi ed from rat liver and suggested to be distinct from other mammalian EHs (mEH, sEH, leukotriene-A 4 hydrolase) by its molecular weight as well as substrate and inhibitor spectrum. However, hepoxilin hydrolase is still only incompletely characterized and the amino acid sequence is not reported to date. The purifi cation scheme used for the isolation of hepoxilin hydrolase ( 30 ) is quite similar to the procedure used for the isolation of rat liver sEH ( 53 ) . We assume that the hepoxilin hydrolase activity in the enzyme preparation published previously is due to an invisible contamination by sEH. The assignment of the enzymatic activity to an incorrect polypeptide might be due to the obviously low abundance of sEH in livers of untreated rats, which would also explain the striking activity difference between the two enzymes.
These results suggested a physiological role of sEH in hepoxilin metabolism. Analysis of mouse liver cytosol by gel permeation chromatography followed by activity measurements against HxA 3 , 14,15-EET (an excellent sEH substrate), and 5,6-EET (a rather poor sEH substrate) and oxides. Indeed, we have shown that purifi ed microsomal epoxide hydrolase does not turn over hepoxilins. In addition, ACU inhibited hepoxilin metabolism by purifi ed rat sEH as well as liver cytosolic preparations with an IC 50 value of ‫ف‬ 1 nM. These results are further supported by the LC-MS/MS analysis of lipid fractions prepared from organs of sEH WT and sEH Ϫ / Ϫ animals. The liver homogenates of sEH Ϫ / Ϫ mice show elevated basal levels of hepoxilins, particularly HxB 3 , whereas trioxilin levels are signifi cantly decreased compared with the WT animals ( Fig. 7A ) . The pretreatment of organ extracts with arachidonic acid presumably leads to a strong production of hepoxilin precursors such as 12-HPETE. In this case, both HxA 3 and HxB 3 signifi cantly accumulate in the livers of sEH Ϫ / Ϫ animals and only a slow turnover to trioxilins is detected ( Fig. 7B ). An arachidonic acid pretreatment better refl ects the actual enzyme capacity of the organ analyzed, whereas in the basal state, compensatory mechanisms of lipid metabolism might be of importance. Quit unexpected were the large amounts of HxB 3 , particularly, in the livers of sEH Ϫ / Ϫ mice whereas HxA 3 did not accumulate to that extent. HxA 3 has been shown to be a substrate for glutathione-S-transferases and the glutathione-conjugated metabolite maintains biologic activity ( 32, 37 ) . Due to the high expression level of GSTs in the liver, one would expect a lack of hepoxilin accumulation, which is only seen for the HxA 3 regioisomer ( Fig. 7 ) . Therefore, glutathione conjugation of HxB 3 does not seem to be an important pathway in the liver. Note that the glutathione derivative of HxB 3 has not been detected in vivo to date. In contrast, HxA 3 seem to be preferentially glutathionylated in livers of sEH Ϫ / Ϫ animals, which might also be the case in other organs, when the epoxide hydrolysis pathway is blocked. Taken together, our results strongly suggest that mammalian sEH is the key enzyme responsible for hepoxilin metabolism and indeed, identical to previously reported hepoxilin hydrolase. Other mammalian epoxide hydrolase contributes, if at all, only partly to this metabolic pathway, depending on the tissue analyzed.
Our inhibitory analyses using sEHIs clearly show a complete block of hepoxilin hydrolysis in the liver. Therefore, possible undesirable effects of sEH inhibitors, which are in development for a number of applications, should be considered. Lipid signaling pathways other then the mostly targeted EET pathways might be affected with, to our knowledge, unknown consequences. This is even more important as EETs and hepoxilins seem to have somewhat opposing effects. Although the action of EETs are generally considered anti-infl ammatory (15) (16) (17) , hepoxilins instead are suspected to have pro-infl ammatory effects. In psoriatic lesions, elevated levels of hepoxilins and trioxilins have been detected ( 38 ) . Furthermore, HxA 3 has recently been identifi ed as a pathogen elicited epithelial chemoattractant. HxA 3 leads to neutrophil migration across epithelial barriers in response to mucosal infl ammation in the intestine or lung ( 39, 40 ) . An inhibition of sEH might therefore cause enhanced release of hepoxilins at infl ammatory sites. Such a deregulation might trigger pathophysiological effects of infl ammation seen, for exOnly sEHIs but not mEHIs quantitatively inhibited hepoxilin turnover in cytosolic as well as microsomal liver preparations of WT animals. mEH shows a substrate preference for bulky, cis -substituted epoxides compared with the sEH, which accepts both cis -and trans -substituted ep- ample, in infl ammatory bowel disease, cystic fi brosis, or chronic obstructive pulmonary disease of the lung.
In conclusion, hepoxilins are excellent substrates for mammalian sEH in vitro and in vivo. Our fi ndings suggest that sEH is identical to liver hepoxilin hydrolase and plays an important role in the physiological regulation of hepoxilins with important implications in particular for infl ammatory diseases.
